fenofibrate has been researched along with isoproterenol in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Botion, LM; Delpuerto, HL; Ferreira, AV; Mario, EG; Martins, AS; Parreira, GG; Porto, LC | 1 |
| Hang, ZG; Wu, J; Yu, B; Yuan, J; Zhong, XK; Zhou, LW | 1 |
| Cachofeiro, V; Davel, AP; Fukuda, LE; Lahera, V; Lopes, LR; Rossoni, LV; Verissimo-Filho, S | 1 |
| Han, ZG; Wu, J; Yuan, J | 1 |
| Althurwi, HN; El-Kadi, AO; Elshenawy, OH | 1 |
| Guo, YY; Wang, BX; Wang, YQ; Wu, Y | 1 |
| Cheng, X; Li, P; Luo, S; Pan, C | 1 |
| Balakumar, P; Garg, M; Kalra, S; Khanna, D | 1 |
1 review(s) available for fenofibrate and isoproterenol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for fenofibrate and isoproterenol
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.
Topics: Acyl-CoA Oxidase; Adipocytes; Adrenergic beta-Agonists; Animals; Cell Separation; Diet; Fenofibrate; Hepatic Insufficiency; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Isoproterenol; Lipid Metabolism; Lipids; Lipolysis; Lipoprotein Lipase; Liver; Male; Orotic Acid; PPAR alpha; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Role of peroxisome proliferator-activated receptor alpha activation in acute myocardial damage induced by isoproterenol in rats.
Topics: Animals; Creatine Kinase; Energy Metabolism; Fatty Acids, Nonesterified; Fenofibrate; Heart; Isoproterenol; L-Lactate Dehydrogenase; Male; PPAR alpha; Rats; Rats, Wistar | 2008 |
Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; Endothelium, Vascular; Fenofibrate; Isoproterenol; Male; NG-Nitroarginine Methyl Ester; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Potassium Chloride; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Superoxide Dismutase; Thiazolidinediones; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2008 |
[Fenofibrate improves energy metabolism and attenuates isoproterenol induced acute myocardial ischemic injury in rats via PPAR alpha activation].
Topics: Animals; Disease Models, Animal; Energy Metabolism; Fenofibrate; Isoproterenol; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; PPAR alpha; Rats; Rats, Wistar | 2008 |
Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Cardiomegaly; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Fenofibrate; Gene Expression Regulation, Enzymologic; Hydroxyeicosatetraenoic Acids; Hypolipidemic Agents; Isoproterenol; Male; Rats; Rats, Sprague-Dawley | 2014 |
[The effect of relgulation of PPAR-α on cardiac hypertrophy and the relationship between the effect of PPAR-α with PI3K/Akt/mTOR pathway].
Topics: Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; Fenofibrate; Humans; Isoproterenol; Myocytes, Cardiac; Myosin Heavy Chains; Phosphatidylinositol 3-Kinases; PPAR alpha; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate.
Topics: Animals; Cells, Cultured; Energy Metabolism; Fatty Acids; Fenofibrate; Heart Failure; Hypolipidemic Agents; Ion Channels; Isoproterenol; Male; Mitochondrial Proteins; Myocytes, Cardiac; Necrosis; PPAR alpha; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Uncoupling Protein 2 | 2015 |
Chronic oral administration of low-dose combination of fenofibrate and rosuvastatin protects the rat heart against experimentally induced acute myocardial infarction.
Topics: Administration, Oral; Animals; Cardiotonic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Heart; Isoproterenol; Male; Myocardial Infarction; Oxidative Stress; Rats; Rats, Wistar; Rosuvastatin Calcium | 2016 |